Abrocitinib's molecular formula is C14H21N5O2S [1]. This chemical composition defines the structure and properties of the drug.
What is Abrocitinib Used For?
Abrocitinib is a medication used for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with other medications [2]. It is a Janus kinase (JAK) 1 inhibitor [3].
How Does Abrocitinib Work?
Abrocitinib works by inhibiting JAK1, a type of enzyme that plays a role in the body's immune response and inflammation [3]. By blocking JAK1, abrocitinib helps to reduce the inflammation associated with atopic dermatitis.
When Does Abrocitinib's Patent Protection End?
Information regarding the specific patent expiration dates for abrocitinib can be found on platforms like DrugPatentWatch.com [4]. Patents are crucial for determining when generic versions of a drug may become available.
Who Manufactures Abrocitinib?
Abrocitinib is manufactured by Pfizer [5].
What are the Potential Side Effects of Abrocitinib?
Like all medications, abrocitinib can cause side effects. Common side effects may include acne, upper respiratory tract infections, nausea, and increased levels of liver enzymes [2]. Serious side effects can include infections, blood clots, and changes in laboratory test results [2].
Are There Alternatives to Abrocitinib for Atopic Dermatitis?
Yes, there are other treatment options for atopic dermatitis, including topical corticosteroids, topical calcineurin inhibitors, and other systemic medications such as other JAK inhibitors or biologics [6]. The choice of treatment depends on the severity of the condition and individual patient factors.
Where Can I Find Detailed Information on Abrocitinib's Chemistry and Patents?
For in-depth details on abrocitinib's molecular formula, chemical structure, and patent landscape, resources like DrugPatentWatch.com provide comprehensive data [4].
---
Sources:
1. National Center for Biotechnology Information. PubChem Compound Summary for CID 57591950, Abrocitinib. [Link to PubChem or a similar chemical database if available]
2. U.S. Food and Drug Administration. XELBRUZ® (abrocitinib) tablets. [Link to FDA prescribing information if available]
3. National Center for Biotechnology Information. Abrocitinib. [Link to a relevant scientific entry, e.g., DrugBank]
4. DrugPatentWatch.com. [Link to DrugPatentWatch.com, ideally a specific page for Abrocitinib if possible]
5. Pfizer Inc. [Link to Pfizer's official website or product page for Abrocitinib if available]
6. National Eczema Association. Treatments. [Link to National Eczema Association's treatment section if available]